Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT
Bipin N. Savani,
Myriam Labopin,
Didier Blaise,
Dietger Niederwieser,
Fabio Ciceri,
Arnold Ganser,
Renate Arnold,
Boris Afanasyev,
Stephane Vigouroux,
Noel Milpied,
Michael Hallek,
Jan J. Cornelissen,
Rainer Schwerdtfeger,
Emmanuelle Polge,
Frédéric Baron,
Jordi Esteve,
Norbert C. Gorin,
Christoph Schmid,
Sebastian Giebel,
Mohamad Mohty,
Arnon Nagler
Affiliations
Bipin N. Savani
Vanderbilt University Medical Center, Nashville, TN, USA
Myriam Labopin
EBMT Paris Study Office/CEREST-TC, Paris, France;Department of Haematology, Saint Antoine Hospital, Paris, France;INSERM UMR 938, Paris, France;Université Pierre et Marie Curie, Paris, France
Didier Blaise
Département d’Hématologie - Centre de Recherche en Cancérologie de Marseille - Aix-Marseille University, Institut Paoli Calmettes, Marseille, France
Dietger Niederwieser
University Hospital Leipzig, Hematology, Oncology and Hemostaseology Divisions, Germany
Fabio Ciceri
Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy
Arnold Ganser
Hannover Medical School - Department of Haematology Hemostasis Oncology and Stem Cell Transplantation, Hannover, Germany
Renate Arnold
Charité Universitätsmedizin Berlin, Campus Virchow Klinikum – Medizinische Klinik m. S. Hämatologie/Onkologie, Berlin, Germany
Boris Afanasyev
Saint Petersburg State Medical Pavlov University, Ratsa Gorbacheva Memorial Children’s Institute, Hematology and Transplantology, St. Petersburg, Russia
Stephane Vigouroux
CHU Bordeaux - Hôpital Haut-leveque, Pessac, France
Noel Milpied
CHU Bordeaux - Hôpital Haut-leveque, Pessac, France
Michael Hallek
University of Cologne, Department of Medicine, Germany
Jan J. Cornelissen
ErasmusMC Cancer Institute, Erasmus University Medical Center, Rotterdam, the Netherlands
Rainer Schwerdtfeger
Department of Haematology, Oncology Helios-Klinikum Berlin-Buch, Germany
Emmanuelle Polge
EBMT Paris Study Office/CEREST-TC, Paris, France;Department of Haematology, Saint Antoine Hospital, Paris, France;INSERM UMR 938, Paris, France;Université Pierre et Marie Curie, Paris, France
Frédéric Baron
Department of Medicine, Division of Hematology, University of Liège, Belgium
Jordi Esteve
Department of Hematology, Hospital Clinic, Barcelona, Spain
Norbert C. Gorin
Department of Hematology, Saint Antoine Hospital, APHP and University UPMS, Paris, France
Christoph Schmid
Klinikum Augsburg, Department of Hematology and Oncology, University of Munich, Augsburg, Germany
Sebastian Giebel
Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Poland
Mohamad Mohty
EBMT Paris Study Office/CEREST-TC, Paris, France;Department of Haematology, Saint Antoine Hospital, Paris, France;INSERM UMR 938, Paris, France;Université Pierre et Marie Curie, Paris, France
Arnon Nagler
EBMT Paris Study Office/CEREST-TC, Paris, France;Hematology Division, Chaim Sheba Medical Center, Tel Hashomer, Israel
Increasing numbers of patients are receiving reduced intensity conditioning regimen allogeneic hematopoietic stem cell transplantation. We hypothesized that the use of bone marrow graft might decrease the risk of graft-versus-host disease compared to peripheral blood after reduced intensity conditioning regimens without compromising graft-versus-leukemia effects. Patients who underwent reduced intensity conditioning regimen allogeneic hematopoietic stem cell transplantation from 2000 to 2012 for acute leukemia, and who were reported to the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation were included in the study. Eight hundred and thirty-seven patients receiving bone marrow grafts were compared with 9011 peripheral blood transplant recipients after reduced intensity conditioning regimen. Median follow up of surviving patients was 27 months. Cumulative incidence of engraftment (neutrophil ≥0.5×109/L at day 60) was lower in bone marrow recipients: 88% versus 95% (P
